Saridegib  (Synonyms: IPI-926; Patidegib)

Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.

Smo^[1].

Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

504.77

C₂₉H₄₈N₂O₃S

1037210-93-7

Solid

White to off-white

CC1=C(C[C@@]2([H])[C@@]3([H])CC[C@@]4([H])[C@]2(C)CC[C@@H](NS(C)(=O)=O)C4)[C@@]3([H])CC[C@@]([C@@H]5C)(C1)O[C@@]6([H])[C@@]5([H])NC[C@@H](C)C6

Room temperature in continental US; may vary elsewhere.

• [1]. Ko AH, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5.  [Content Brief]